Javier Jimenez-Torres

Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 14, 2026

Climate disasters and cancer care: the Valencia DANA as a case for system resilience.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 04, 2026

Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 17, 2025

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 24, 2025

Emerging Targeted Therapies for HER2-Mutant NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 02, 2025

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Journal: Cancers

Published: September 21, 2025

Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 31, 2025

Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 24, 2025

Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond.

Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond.

Climate disasters and cancer care: the Valencia DANA as a case for system resilience.

Climate disasters and cancer care: the Valencia DANA as a case for system resilience.

Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.

Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Emerging Targeted Therapies for HER2-Mutant NSCLC.

Emerging Targeted Therapies for HER2-Mutant NSCLC.

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions.

Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions.

Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey.

Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey.

Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.

Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.